Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
Recruiting
Phase 1
Interventional Study
XIAP Deficiency
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 2 and older
- Sex
- Male
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 12 (estimated)
- Sponsor
- Children's Hospital Medical Center, Cincinnati · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male patients
* Diagnosis of XIAP deficiency
* Patients ≥2 years of age
* Serum IL-18 ≥600 pg/mL (approximately 25% above the lab-defined upper limit of normal of 477 pg/mL)
* Able to take enteral medication
Exclusion Criteria:
* Renal failure requiring dialysis
* Total bili…
Contacts